.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

US Department of Justice
Harvard Business School
Deloitte
McKesson
Boehringer Ingelheim
Medtronic
Colorcon
AstraZeneca
Covington
UBS

Generated: September 20, 2017

DrugPatentWatch Database Preview

PROQUIN XR Drug Profile

« Back to Dashboard

What is the patent landscape for Proquin Xr, and what generic Proquin Xr alternatives are available?

Proquin Xr is a drug marketed by Depomed Inc and is included in one NDA. There are four patents protecting this drug.

This drug has forty-five patent family members in seventeen countries.

The generic ingredient in PROQUIN XR is ciprofloxacin hydrochloride. There are thirty-one drug master file entries for this compound. Seventy-two suppliers are listed for this compound. Additional details are available on the ciprofloxacin hydrochloride profile page.

Summary for Tradename: PROQUIN XR

Patents:4
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Bulk Api Vendors: see list32
Patent Applications: see list1,382
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:PROQUIN XR at DailyMed

Pharmacology for Tradename: PROQUIN XR

Ingredient-typeQuinolones
Drug ClassQuinolone Antimicrobial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Depomed Inc
PROQUIN XR
ciprofloxacin hydrochloride
TABLET, EXTENDED RELEASE;ORAL021744-001May 19, 2005DISCNNoNo► Subscribe► SubscribeY ► Subscribe
Depomed Inc
PROQUIN XR
ciprofloxacin hydrochloride
TABLET, EXTENDED RELEASE;ORAL021744-001May 19, 2005DISCNNoNo► Subscribe► SubscribeY ► Subscribe
Depomed Inc
PROQUIN XR
ciprofloxacin hydrochloride
TABLET, EXTENDED RELEASE;ORAL021744-001May 19, 2005DISCNNoNo► Subscribe► SubscribeY ► Subscribe
Depomed Inc
PROQUIN XR
ciprofloxacin hydrochloride
TABLET, EXTENDED RELEASE;ORAL021744-001May 19, 2005DISCNNoNo► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: PROQUIN XR

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Depomed Inc
PROQUIN XR
ciprofloxacin hydrochloride
TABLET, EXTENDED RELEASE;ORAL021744-001May 19, 2005► Subscribe► Subscribe
Depomed Inc
PROQUIN XR
ciprofloxacin hydrochloride
TABLET, EXTENDED RELEASE;ORAL021744-001May 19, 2005► Subscribe► Subscribe
Depomed Inc
PROQUIN XR
ciprofloxacin hydrochloride
TABLET, EXTENDED RELEASE;ORAL021744-001May 19, 2005► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: PROQUIN XR

Country Document Number Estimated Expiration
South Korea20000048500► Subscribe
Spain2213836► Subscribe
Spain2248908► Subscribe
Portugal1294363► Subscribe
Japan2009040787► Subscribe
Japan2001500879► Subscribe
Canada2412671► Subscribe
Hong Kong1027298► Subscribe
Australia8138698► Subscribe
MexicoPA02012614► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: PROQUIN XR

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB12/058United Kingdom► SubscribePRODUCT NAME: A COMBINATION OF CIPROFLOXACIN AND DEXAMETHASONE, PREFERABLY CIPROFLOXACIN HYDROCHLORIDE AND DEXAMETHASONE; REGISTERED: DK DE/11/3337/001/DC 20120808; UK PL000649/0381-0001 20121003
C0012France► SubscribePRODUCT NAME: COMBINAISON DE CIPROFLOXACINE ET DE DEXAMETHASONE, EN PARTICULIER DE CHLORHYDRATE DE CIPROFLOXACINE ET DE DEXAMETHASONE; NAT. REGISTRATION NO/DATE: NL 41308 20121214; FIRST REGISTRATION: 48976 20120808
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Covington
Mallinckrodt
Farmers Insurance
US Department of Justice
QuintilesIMS
Cerilliant
Novartis
Queensland Health
Argus Health
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot